Sara T'sas

Gent, VLG 9000, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Peptide hydrogels as slow-release formulations of protein therapeutics: case study of asparaginase-loaded hydrogels.

Peptide hydrogels as slow-release formulations of protein therapeutics: case study of asparaginase-loaded hydrogels.

Journal: Biomaterials science
Published: June 17, 2025

CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy.

CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy.

Journal: Pharmacological research
Published: December 19, 2024

A dual role for PSIP1/LEDGF in T cell acute lymphoblastic leukemia.

A dual role for PSIP1/LEDGF in T cell acute lymphoblastic leukemia.

Journal: Science advances
Published: November 01, 2024

A human-like glutaminase-free asparaginase is highly efficacious in ASNSlow leukemia and solid cancer mouse xenograft models.

A human-like glutaminase-free asparaginase is highly efficacious in ASNSlow leukemia and solid cancer mouse xenograft models.

Journal: Cancer letters
Published: October 28, 2024

Tet2 is a tumor suppressor in the preleukemic phase of T-cell acute lymphoblastic leukemia.

Tet2 is a tumor suppressor in the preleukemic phase of T-cell acute lymphoblastic leukemia.

Journal: Blood advances
Published: October 24, 2023

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia.

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia.

Journal: HemaSphere
Published: August 14, 2023

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma.

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma.

Journal: Cancers
Published: November 30, 2022

Myb drives B-cell neoplasms and myeloid malignancies in vivo.

Myb drives B-cell neoplasms and myeloid malignancies in vivo.

Journal: Blood advances
Published: August 16, 2021

Direct and indirect anti-leukemic properties of activity-on-target interferons for the treatment of T-cell acute lymphoblastic leukemia.

Direct and indirect anti-leukemic properties of activity-on-target interferons for the treatment of T-cell acute lymphoblastic leukemia.

Journal: Haematologica
Published: April 05, 2021

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.

Journal: The Journal of experimental medicine
Published: October 24, 2020

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies.

Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies.

Journal: Scientific reports
Published: March 08, 2019

ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.

ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.

Journal: Haematologica
Published: September 30, 2018
Showing 1-12 of 12

Last Updated: 09/26/2026